UPDATE: Raymond James on AngioDynamics Buy Reiteration: Firm Highlights Accelerating Revenue Growth Over Next 3 Years 'Culminating In Double-Digit Growth In F24'; Sees AlphaVac As Co.'s Biggest Ever Product Opportunity Launching In The Fall